Onconova promotes Guerin to COO/CFO, Makovski Silverstein to head corp dev; Oler resigns

Traws Pharma, Inc.

Mark Guerin appointed COO/CFO; salary raised to $475K; receives 50,250 options and 16,500 RSUs.
Dr. Adar Makovski Silverstein promoted to Senior Director and Head of Corporate Development.
Avi Oler, SVP Corporate Development and General Counsel, resigns effective June 17, 2022.
Guerin's equity awards vest over three years: RSUs 33/33/34%, options 1/3 at year 1 then monthly.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Abraham N. Oler

Senior Vice President, Corporate Development and General Counsel

TRAW · Traws Pharma, Inc.

Effective: 2022-06-17
Filed: June 13, 2022, 7:59 PM ET

On June 10, 2022, Abraham N. Oler, Senior Vice President, Corporate Development and General Counsel, notified the company of his resignation effective June 17, 2022 to pursue an opportunity outside the biotechnology sector.

Appointed

Mark Guerin

Chief Operating Officer

TRAW · Traws Pharma, Inc.

Effective: 2022-06-10
Filed: June 13, 2022, 7:59 PM ET

On June 10, 2022, Onconova Therapeutics, Inc. (the “Company”) appointed Mark Guerin, as Chief Operating Officer in addition to his current role as Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Abraham N. Oler resigned as Senior Vice President, Corporate Development and General Counsel at Traws Pharma, Inc..

Action: resigned
Role: Senior Vice President, Corporate Development and General Counsel

Exact text from the filing

On June 10, 2022, Abraham N. Oler, Senior Vice President, Corporate Development and General Counsel, notified the company of his resignation effective June 17, 2022 to pursue an opportunity outside the biotechnology sector.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Guerin was appointed as Chief Operating Officer at Traws Pharma, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On June 10, 2022, Onconova Therapeutics, Inc. (the “Company”) appointed Mark Guerin, as Chief Operating Officer in addition to his current role as Chief Financial Officer.

View on SEC.gov

Traws Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-070355

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.